John Wilding

Professor of Medicine

University of Liverpool

United Kingdom

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Clinical Nutrition

100%

Internal Medicine

30%

Diabetology

100%

Cardiometabolic Health

50%

Obesity

50%

Glucose Metabolism

40%

Insulin Resistance

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

How are treatment outcomes for people with severe obesity ImPROved by GROUP-based behavioural intervention?

Open Date: 2021-05-01

Close Date: 2026-04-30

Grant: Close

Type 2 Diabetes (T2D) in 16 – 40 year olds: A Multifactorial Management Intervention to Address Multimorbidity in Early-Onset T2D in Adults (The M3 Research Programme)

Open Date: 2021-03-01

Close Date: 2026-02-28

Grant: Close

MECNUT: Impact of dietary exposure to emulsifiers on the intestinal mucosa - implications for inflammatory bowel disease and metabolic syndrome

Open Date: 2017-11-01

Close Date: 2021-03-30

Grant: Close

Patients' expectations, beliefs and attitudes towards glucose-lowering drugs and their effects on body weight in Type 2 diabetes: a prospective study and pilot intervention.

Open Date: 2011-09-01

Close Date: 2014-08-31

Grant: Close

Benefits of weight loss in obese patients with asthma: mechanical or immunological mechanisms?

Open Date: 2004-10-01

Close Date: 2008-12-31

John Wilding

Professor of Medicine

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Recent Grants

Articles20

Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation

Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database

Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.

1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

The double burden of malnutrition in individuals: Identifying key challenges and re-thinking research focus.

Obesity pharmacotherapy in older adults: a narrative review of evidence.

SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.

New insights into the treatment of obesity

Adipocytes in obesity: A perfect reservoir for SARS-CoV-2?

Association of Cardiac Biomarkers with Major Adverse Cardiovascular Events in High-risk Patients with Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)

Obesity: medical management

Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation

Collaborators11

Jason Christian Grovenor Halford

Timothy Jackson

Rachel Batterham

Gary A Wittert

Francesco Giorgino

Kirsi Pietiläinen

Sizheng Steven Zhao

Francisco Lopez-Jimenez

Emanuele Di Angelantonio

Roy Taylor

Carel Le Roux

How do I reach out?